RayKnowChina Research Map
Shortlist0

Shandong University

山东大学

JinanUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.4%Leads under 1 in 100 of China's research papers on NPC

Led 10 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueEBV & screening

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Qilu Hospital of Shandong University4
  2. Third Hospital of Shandong University Counted in the group total1
  3. Zibo Central Hospital1
  4. Second Hospital of Shandong University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.7%Leads about 1 in 60 of China's research papers on ESCC

Led 49 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
1
Research papers it led
49
Trials it led
6
Share of China's trials
1.1%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025
ThemesMolecular markers & genomicsEarly detection & endoscopyImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Qilu Hospital of Shandong University31
  2. Second Hospital of Shandong University10
  3. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Counted in the group total1
  4. Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine Counted in the group total1
  5. Shandong Provincial ENT Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Ivor Lewis minimally invasive oesophagectomy versus McKeown approach: short-term benefits and mid-term equivalence in a randomized trial for oesophageal squamous cell carcinoma.2026Surgical endoscopyRCTFree full text
  2. The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial.2024Thoracic cancerRCTFree full text
  3. Optimal concentration of Lugol's solution for detecting early esophageal carcinoma: A randomized controlled trial.2023Journal of gastroenterology and hepatologyRCT
  4. Development and Validation of Esophageal Squamous Cell Carcinoma Risk Prediction Models Based on an Endoscopic Screening Program.2023JAMA network openFree full text
  5. Artificial intelligence-aided optical biopsy improves the diagnosis of esophageal squamous neoplasm.2025World journal of gastroenterologyFree full text
Trials on ClinicalTrials.gov6
  1. Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell CarcinomaRecruitingNCT07430579Lead sponsorN/AStart 2024-12
  2. Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal DissectionActive, not recruitingNCT07757906Lead sponsorN/AStart 2026-08
  3. Neoadjuvant Immunotherapy to ESCCWithdrawnNCT04625543Lead sponsorPhase 2Start 2020-12
  4. Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell CarcinomaCompletedNCT03759756Lead sponsorStart 2018-12
  5. Early Detection of Head and Neck Superficial Squamous Cell Carcinoma in Patients With Esophagus Squamous Cell CarcinomaStatus unknownNCT03700398Lead sponsorN/AStart 2017-10
  6. Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine StainingCompletedNCT03180944Lead sponsorPhase 2Start 2017-09

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.1%Leads about 1 in 94 of China's research papers on HCC

Led 157 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
157
Trials it led
4
Share of China's trials
0.3%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 222025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Hospitals counted here

  1. Qilu Hospital of Shandong University80
  2. Second Hospital of Shandong University41
  3. Third Hospital of Shandong University Counted in the group total3
  4. Children's Hospital, Shandong University Counted in the group total3
  5. Weihai Municipal Hospital Counted in the group total2
  6. Shandong Provincial ENT Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. MRI-based preoperative markers combined with narrow-margin hepatectomy result in higher early recurrence.2022European journal of radiologyRCT
  2. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.2024Journal of hepatology
  3. Reduced visceral adipose tissue area linked to early recurrence in HCC patients with HBV: a parallel mediation analysis.2026Abdominal radiology (New York)
  4. Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2025Academic radiology
  5. Nonlinear relationship between age and the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.2025BMC infectious diseasesFree full text
Trials on ClinicalTrials.gov6
  1. Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionRecruitingNCT06454578Lead sponsorPhase 2Start 2024-07
  2. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNot yet recruitingNCT07350070Study sitePhase 2Start 2025-12
  3. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  4. Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic CholangiocarcinomaStatus unknownNCT05327907Lead sponsorStart 2020-11
  5. Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular CarcinomaCompletedNCT05017922Lead sponsorN/AStart 2017-01
  6. Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular CarcinomaStatus unknownNCT06571396Lead sponsorStart 2014-04

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.4%Leads about 1 in 69 of China's research papers on Stomach cancer

Led 141 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
16
Research papers it led
141
Trials it led
45
Share of China's trials
3.1%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs

Hospitals counted here

  1. Qilu Hospital of Shandong University80
  2. Second Hospital of Shandong University22
  3. Weihai Municipal Hospital12
  4. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Counted in the group total9
  5. Shandong Provincial Third Hospital Counted in the group total2
  6. Affiliated Hospital of Shandong University of TCM2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Vagus Nerve Preservation for Early Distal Gastric Cancer With Monitoring and Indocyanine Green Labeling: A Randomized Clinical Trial.2025JAMA surgeryRCTFree full text
  2. Safety and efficacy of traction robot-assisted endoscopic submucosal dissection for early gastric cancer: a randomized pilot trial.2026EndoscopyRCT
  3. Efficacy of quadratus lumborum block type 3 on postoperative cell-mediated immunity and analgesia for laparoscopic radical gastrectomy: a prospective randomized controlled trial.2025Surgical endoscopyRCT
  4. Optical enhancement with magnification versus white-light endoscopy for detecting gastric intestinal metaplasia and neoplasia: a randomized controlled trial.2025Gastrointestinal endoscopyRCT
  5. N6-methyladenosine-regulated exosome biogenesis orchestrates an immunosuppressive pre-metastatic niche in gastric cancer peritoneal metastasis.2025Cancer communications (London, England)Free full text
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric CancerRecruitingNCT07537348Lead sponsorPhase 2Start 2026-01
  2. Multi-center Prospective Validation of Real-Time AI-EGGIM SystemNot yet recruitingNCT07915843Lead sponsorStart 2026-11
  3. Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric CancerRecruitingNCT07635836Lead sponsorN/AStart 2026-05
  4. Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric CancerRecruitingNCT07537361Lead sponsorPhase 2Start 2026-01
  5. One-Click Autofocus Versus Segmented Focus in Gastric EndoscopyNot yet recruitingNCT07664813Lead sponsorN/AStart 2026-06
  6. Early Postoperative Intervention in Gastric Cancer PatientsEnrolling by invitationNCT07444099Lead sponsorN/AStart 2026-02

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Retinoblastoma New since 2021

Led 2 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Children's Hospital, Shandong University1
  2. Qilu Hospital of Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.9%Leads about 1 in 51 of China's research papers on Osteosarcoma

Led 44 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
44
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 0020242025: 002025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.0%Leads none of China's research papers on Gastrointestinal stromal tumour

Led 0 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.8%Leads under 1 in 100 of China's research papers on Neuroblastoma ▼ from 1.5%

Led 9 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Qilu Hospital of Shandong University5
  2. Second Hospital of Shandong University1
  3. Qilu Children's Hospital, Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma ▼ from 3.6%

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Qilu Hospital of Shandong University1
  2. Children's Hospital, Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.7%Leads about 1 in 60 of China's research papers on Myeloma ▲ from 1.1%

Led 28 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
28
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesDrug combinationsDiagnosis, MRD & riskKidney & bone complications

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine9
  2. Second Hospital of Shandong University7
  3. Qilu Hospital of Shandong University3
  4. Affiliated Hospital of Shandong University of Traditional Chinese Medicine3
  5. Zibo Central Hospital, Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.2025Cancer medicineFree full text
  2. Retrospective cohort study on alkaline phosphatase and ICU mortality rate of multiple myeloma.2025Scientific reportsFree full text
  3. Relationship between serum anion gap and mortality in ICU in multiple myeloma patients in the MIMIC database: A retrospective cohort study.2025PloS oneFree full text
  4. Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.2025BMC cancerFree full text
  5. Guizhi Fuling decoction protects against bone destruction via suppressing exosomal ERK1 in multiple myeloma.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
Trials on ClinicalTrials.gov6
  1. Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple MyelomaRecruitingNCT06039735Lead sponsorStart 2023-11
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  3. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  4. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  6. Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple MyelomaStatus unknownNCT06574958Lead sponsorEarly phase 1Start 2024-04

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025
ThemesChildren

Hospitals counted here

  1. Qilu Hospital of Shandong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
3.6%Leads about 1 in 27 of China's research papers on Aplastic anaemia ▲ from 1.2%

Led 15 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
15
Trials it led
2
Share of China's trials
2.1%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesChildrenStem cell transplantImmunosuppressive treatment

Hospitals counted here

  1. Affiliated Hospital of Shandong University of Traditional Chinese Medicine5
  2. Children's Hospital, Shandong University3
  3. Qilu Hospital of Shandong University3
  4. Second Hospital of Shandong University2
  5. Third Hospital of Shandong University Counted in the group total1
  6. Weihai Municipal Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.0%Leads about 1 in 100 of China's research papers on HLH

Led 4 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 002025
ThemesEBV & infection triggersDiagnosis & prognosisChildren

Hospitals counted here

  1. Qilu Hospital of Shandong University2
  2. Shandong Provincial Third Hospital Counted in the group total1
  3. Children's Hospital, Shandong University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
0.6%Leads under 1 in 100 of China's research papers on Beta thalassaemia

Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
2.2%Leads about 1 in 45 of China's research papers on Haemophilia A New since 2021

Led 6 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Hospitals counted here

  1. Qilu Hospital of Shandong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
5.9%Leads about 1 in 17 of China's research papers on Fanconi anaemia ▲ from 3.7%

Led 4 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Children's Hospital, Shandong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.9%Leads about 1 in 54 of China's research papers on NMOSD ▲ from 0.4%

Led 9 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025
ThemesAntibodies & diagnosisImagingAcute attack treatment

Hospitals counted here

  1. Qilu Hospital of Shandong University7
  2. Second Hospital of Shandong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
2.2%Leads about 1 in 45 of China's research papers on Myasthenia gravis ▼ from 2.9%

Led 11 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025
ThemesAntibodies & diagnosisStandard immunotherapyThymus & thymectomy

Hospitals counted here

  1. Qilu Hospital of Shandong University6
  2. Second Hospital of Shandong University2
  3. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Lambert-Eaton myasthenic syndrome presenting with occult mediastinal small cell carcinoma and positivity for anti-CV2/CRMP5 and anti-SOX1 antibodies: a case report.2025BMC neurologyFree full text
  2. Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study.2025Journal of neurology
  3. Isolated dysarthria as the sole manifestation of myasthenia gravis: a case report.2022The Journal of international medical researchFree full text
  4. Lambert-Eaton Myasthenic Syndrome in Lung Cancer.2022Contrast media & molecular imagingFree full text
  5. Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application.2022BioFactors (Oxford, England)
Trials on ClinicalTrials.gov6
  1. A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia GravisNot yet recruitingNCT07298928Study siteN/AStart 2026-03
  2. A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia GravisRecruitingNCT06688435Study sitePhase 1Start 2025-03
  3. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  4. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Study sitePhase 3Start 2024-07
  5. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  6. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Study sitePhase 3Start 2024-09

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
0.8%Leads under 1 in 100 of China's research papers on Moyamoya

Led 3 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025
ThemesImaging & blood flowRevascularisation surgeryChildren

Hospitals counted here

  1. Children's Hospital, Shandong University Counted in the group total1
  2. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Counted in the group total1
  3. Second Hospital of Shandong University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1.2025International journal of developmental neuroscience : the official journal of the International Society for Developmental NeuroscienceFree full text
  2. The effect of dilated cardiomyopathy with moyamoya disease in a 31-year-old Chinese man: A case report.2022MedicineFree full text
  3. Treatment strategies of ruptured intracranial aneurysms associated with moyamoya disease.2021British journal of neurosurgery

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
0.9%Leads under 1 in 100 of China's research papers on Biliary atresia New since 2021

Led 2 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025
ThemesKasai operationComplications after surgeryScreening & diagnosis

Hospitals counted here

  1. Qilu Hospital of Shandong University Counted in the group total1
  2. Qilu Children's Hospital, Shandong University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
3.4%Leads about 1 in 29 of China's research papers on Anti-NMDA receptor encephalitis ▲ from 1.6%

Led 9 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Qilu Hospital of Shandong University8
  2. Children's Hospital, Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.7%Leads about 1 in 58 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 2.4%

Led 17 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. Qilu Hospital of Shandong University4
  2. Second Hospital of Shandong University3
  3. Affiliated Hospital of Shandong University of Traditional Chinese Medicine3
  4. Affiliated Hospital of Shandong University of Chinese Medicine2
  5. Traditional Chinese Medicine Affiliated Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
2.6%Leads about 1 in 39 of China's research papers on Amyotrophic lateral sclerosis ▲ from 1.0%

Led 20 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. Qilu Hospital of Shandong University13
  2. Affiliated Hospital of Shandong University of Traditional Chinese Medicine4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
1.8%Leads about 1 in 55 of China's research papers on Spinal muscular atrophy New since 2021

Led 1 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Children's Hospital, Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy.2024Human molecular genetics
Trials on ClinicalTrials.gov2
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01
  2. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
1.4%Leads about 1 in 73 of China's research papers on Fabry disease New since 2021

Led 1 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
7.1%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Qilu Hospital of Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Pompe disease

庞贝病
6.7%Leads about 1 in 15 of China's research papers on Pompe disease ▼ from 12.5%

Led 2 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Qilu Hospital of Shandong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
0.9%Leads under 1 in 100 of China's research papers on Duchenne muscular dystrophy ▼ from 3.1%

Led 2 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Second Hospital of Shandong University1
  2. Qilu Hospital of Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
3.5%Leads about 1 in 29 of China's research papers on Alport syndrome

Led 2 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Shandong University of Traditional Chinese Medicine1
  2. Qilu Hospital of Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.5%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 4 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Qilu Hospital of Shandong University2
  2. Second Hospital of Shandong University1
  3. Children's Hospital, Shandong University1
  4. Provincial Hospital, Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.3%Leads about 1 in 75 of China's research papers on Primary biliary cholangitis

Led 4 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 002025

Hospitals counted here

  1. Traditional Chinese Medicine Affiliated Hospital1
  2. Affiliated Hospital of Shandong University of Traditional Chinese Medicine1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
1.0%Leads about 1 in 100 of China's research papers on Primary sclerosing cholangitis New since 2021

Led 1 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Qilu Hospital of Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
2.5%Leads about 1 in 40 of China's research papers on Hirschsprung disease ▼ from 4.3%

Led 4 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Qilu Hospital of Shandong University3
  2. Qilu Children's Hospital, Shandong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
5.8%Leads about 1 in 17 of China's research papers on Leber hereditary optic neuropathy New since 2021

Led 3 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Qilu Hospital of Shandong University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. Teaching NeuroImage: Leber Hereditary Optic Neuropathy With Longitudinal Spinal Cord Lesion Mimicking Spinal Cord Infarction.2022Neurology
  2. Leber's hereditary optic neuropathy plus dystonia caused by the mitochondrial ND1 gene m.4160 T > C mutation.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Leber hereditary optic neuropathy and dystonia overlapping mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes due to m.14459G>A mutation.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

PubMed searchClinicalTrials.gov